Adoptive immunotherapy for cancer: harnessing the T cell response

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548 · see citing works

Coordinated regulation of myeloid cells by tumours

Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,956 · see citing works

A decade of exploring the cancer epigenome—biological and translational implications

Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · see citing works

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823 · see citing works

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · see citing works

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,145 · see citing works

A human memory T cell subset with stem cell–like properties

Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · see citing works

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works

Cancer/testis antigens, gametogenesis and cancer

Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587 · see citing works

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · see citing works

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,441 · see citing works

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works

The Central Role of CD4+ T Cells in the Antitumor Immune Response

Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345 · see citing works

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · see citing works

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

Dudley, M. E., Yang, J. C., Sherry, R. M., Hughes, M. S., Royal, R. E., Kammula, U. S., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,334 · see citing works

The B7 and CD28 receptor families

June, C. H., Bluestone, J. A., Nadler, L. M., & Thompson, C. B. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90080-9 · Cited by 1,296 · see citing works

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,287 · see citing works

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285 · see citing works

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Pulè, M. A., Savoldo, B., Myers, G. D., Rössig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195 · see citing works

Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

Louis, C. U., Savoldo, B., Dotti, G., Pulè, M. A., Yvon, E. S., Myers, G. D., Rössig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,162 · see citing works

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α

Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · see citing works

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., der Meer, D. M. A. B.-V., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,101 · see citing works

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,093 · see citing works

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells

Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,063 · see citing works

Natural selection of tumor variants in the generation of “tumor escape” phenotypes

Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058 · see citing works

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031 · see citing works

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025 · see citing works

Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells

Klebanoff, C. A., Gattinoni, L., Torabi‐Parizi, P., Kerstann, K. W., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503726102 · Cited by 961 · see citing works

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 947 · see citing works

Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth‐Dreese, F. A., Dellemijn, T. A. M., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 927 · see citing works

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

Hunder, N. N. H., Wallen, H. D., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R. M., Jungbluth, A. A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 904 · see citing works

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898 · see citing works

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845 · see citing works

Adoptive immunotherapy for cancer: building on success

Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature reviews. Immunology · doi:10.1038/nri1842 · Cited by 841 · see citing works

Tumor-specific Th17-polarized cells eradicate large established melanoma

Muranski, P. J., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 838 · see citing works

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 822 · see citing works

T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity

Martín‐Orozco, N., Muranski, P. J., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 797 · see citing works

CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

Antony, P. A., Piccirillo, C. A., Akpınarlı, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C., Klebanoff, C. A., Overwijk, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2591 · Cited by 754 · see citing works

Targeting the tumour vasculature: insights from physiological angiogenesis

Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2868 · Cited by 745 · see citing works

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742 · see citing works

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

Staveley-O’Carroll, K. F., Sotomayor, E. M., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D. M., & Levitsky, H. I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1178 · Cited by 702 · see citing works

The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 696 · see citing works

Exploring the Genomes of Cancer Cells: Progress and Promise

Stratton, M. R. (2011) · Science · doi:10.1126/science.1204040 · Cited by 688 · see citing works

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

Pegram, H. J., Lee, J., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 677 · see citing works

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677 · see citing works

The role of CD4+ T cell responses in antitumor immunity

Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672 · see citing works

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

North, R. J. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.4.1063 · Cited by 650 · see citing works

Identification of human cancers deficient in antigen processing.

Restifo, N. P., Esquivel-Guadarrama, F. R., Kawakami, Y., Yewdell, J. W., Mulé, J. J., Rosenberg, S. A., & Bennink, J. R. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.2.265 · Cited by 624 · see citing works

TH17 cells in tumour immunity and immunotherapy

Zou, W., & Restifo, N. P. (2010) · Nature reviews. Immunology · doi:10.1038/nri2742 · Cited by 622 · see citing works

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling

Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586 · see citing works

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells

Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N. S., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 576 · see citing works

Harnessing the biology of IL-7 for therapeutic application

Mackall, C. L., Fry, T. J., & Gress, R. E. (2011) · Nature reviews. Immunology · doi:10.1038/nri2970 · Cited by 572 · see citing works

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550 · see citing works

Loss of Functional Beta2-Microglobulin in Metastatic Melanomas From Five Patients Receiving Immunotherapy

Restifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J. K., Yannelli, J. R., & Rosenberg, S. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.2.100 · Cited by 533 · see citing works

Expression of tumour-specific antigens underlies cancer immunoediting

DuPage, M. J. P., Mazumdar, C., Schmidt, L., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529 · see citing works

Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells

Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527 · see citing works

A novel retinoblastoma therapy from genomic and epigenetic analyses

Zhang, J., Benavente, C. A., McEvoy, J. D., Flores‐Otero, J., Ding, L., Chen, X. '., Ulyanov, A. V., Wu, G., Wilson, M. W., Wang, J., et al. (2012) · Nature · doi:10.1038/nature10733 · Cited by 515 · see citing works

CD8 ⁺ T‐cell memory in tumor immunology and immunotherapy

Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511 · see citing works

gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.277 · Cited by 493 · see citing works

Leukocyte composition of human breast cancer

Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 481 · see citing works

Primary Antitumor Immune Response Mediated by CD4+ T Cells

Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.003 · Cited by 478 · see citing works

The promise and potential pitfalls of chimeric antigen receptors

Sadelain, M., Brentjens, R. J., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 469 · see citing works

Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

Besser, M. J., Shapira‐Frommer, R., Treves, A. J., Zippel, D. B., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462 · see citing works

Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

Rosenberg, S. A., Sherry, R. M., Morton, K. E., Sharfman, W., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U. S., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 460 · see citing works

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

Hinrichs, C. S., Spolski, R. J., Paulos, C. M., Gattinoni, L., Kerstann, K. W., Palmer, D. C., Klebanoff, C. A., Rosenberg, S. A., Leonard, W. J., & Restifo, N. P. (2008) · Blood · doi:10.1182/blood-2007-09-113050 · Cited by 458 · see citing works

Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma

Xie, Y., Akpınarlı, A., Maris, C. H., Hipkiss, E. L., Lane, M. V., Kwon, E. M., Muranski, P. J., Restifo, N. P., & Antony, P. A. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 455 · see citing works

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

Bendle, G. M., Linnemann, C., Hooijkaas, A. I., Bies, L., de Witte, M. A., Jorritsma, A., Kaiser, A., Pouw, N. M. C., Debets, R., Kieback, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2128 · Cited by 447 · see citing works

Th17 cells are long lived and retain a stem cell-like molecular signature

Muranski, P., Borman, Z. A., Kerkar, S. P., Klebanoff, C. A., Ji, Y., Sanchez-Perez, L., Sukumar, M., Reger, R. N., Yu, Z., Kern, S. J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.019 · Cited by 443 · see citing works

CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens

de Almeida, L. G. P., Sakabe, N. J., deOliveira, A. R., da Silva, M. C. C., Mundstein, A. S., Cohen, T., Chen, Y., Chua, R., Gurung, S., Gnjatic, S., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn673 · Cited by 436 · see citing works

Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity

Hinrichs, C., Borman, Z. A., Cassard, L., Gattinoni, L., Spolski, R., Yu, Z.-Y., Sanchez-Perez, L., Muranski, P., Kern, S., Logun, C., et al. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0907448106 · Cited by 407 · see citing works

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Blood · doi:10.1182/blood-2010-01-265041 · Cited by 392 · see citing works

CD4 + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ

Mumberg, D., Monach, P. A., Wanderling, S. S., Philip, M., Toledano, A. Y., Schreiber, R. D., & Schreiber, H. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8633 · Cited by 385 · see citing works

Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4 + T lymphocytes

Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C., Carroll, M. W., Moss, B., Rosenberg, S. A., & Restifo, N. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2982 · Cited by 381 · see citing works

Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

Brentjens, R. J., Yeh, R., Bernal, Y. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.31 · Cited by 380 · see citing works

Host-reactive CD8+ memory stem cells in graft-versus-host disease

Zhang, Y., Joe, G., Hexner, E., Zhu, J., & Emerson, S. G. (2005) · Nature Medicine · doi:10.1038/nm1326 · Cited by 369 · see citing works

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors

Kerkar, S. P., Goldszmid, R. S., Muranski, P. J., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342 · see citing works

CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation

Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339 · see citing works

Genome-wide analysis of cancer/testis gene expression

Hofmann, O., Caballero, O. L., Stevenson, B. J., Chen, Y., Cohen, T., Chua, R. A., Maher, C. A., Panji, S., Schaefer, U., Kruger, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810777105 · Cited by 334 · see citing works

Cancer therapy using a self-replicating RNA vaccine

Han, Y., Zaks, T. Z., Wang, R., Irvine, K. R., Kammula, U. S., Marincola, F. M., Leitner, W. W., & Restifo, N. P. (1999) · Nature Medicine · doi:10.1038/10548 · Cited by 322 · see citing works

Helper T cell diversity and plasticity

Nakayamada, S., Takahashi, H., Kanno, Y., & O’Shea, J. J. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.014 · Cited by 317 · see citing works

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.

Greenberg, P. D., Cheever, M. A., & Fefer, A. (1981) · The Journal of Experimental Medicine · doi:10.1084/jem.154.3.952 · Cited by 314 · see citing works

Apoptotic Death of CD8+ T Lymphocytes After Immunization: Induction of a Suppressive Population of Mac-1+/Gr-1+ Cells

Bronte, V., Wang, M. L., Overwijk, W. W., Surman, D. R., Pericle, F., Rosenberg, S. A., & Restifo, N. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5313 · Cited by 312 · see citing works

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy

Hinrichs, C. S., Borman, Z. A., Gattinoni, L., Yu, Z., Burns, W. R., Huang, J., Klebanoff, C. A., Johnson, L. A., Kerkar, S. P., Yang, S., et al. (2010) · Blood · doi:10.1182/blood-2010-05-286286 · Cited by 309 · see citing works

T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

Stephan, M. T., Ponomarev, V., Brentjens, R. J., et al. (2007) · Nature Medicine · doi:10.1038/nm1676 · Cited by 300 · see citing works

Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P. J., Ji, Y., Hinrichs, C. S., Borman, Z. A., Kerkar, S. P., Scott, C. D., Finkelstein, S. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0503 · Cited by 288 · see citing works

Cancer immunology—analysis of host and tumor factors for personalized medicine

Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 284 · see citing works

Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells

Wrzesinski, C., Paulos, C. M., Kaiser, A., Muranski, P. J., Palmer, D. C., Gattinoni, L., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b88ffc · Cited by 284 · see citing works

Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function

Palmer, D. C., & Restifo, N. P. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.09.009 · Cited by 279 · see citing works

Human T _H 17 Cells Are Long-Lived Effector Memory Cells

Kryczek, I., Zhao, E., Liu, Y., Wang, Y., Vatan, L., Szeliga, W., Moyer, J., Klimczak, A., Lange, A., & Zou, W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002949 · Cited by 278 · see citing works

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., & Marincola, F. M. (1997) · PubMed · Cited by 277 · see citing works

Therapeutic cancer vaccines: Are we there yet?

Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271 · see citing works

Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways

Leitner, W. W., Hwang, L. N., DeVeer, M., Zhou, A., Silverman, R. H., Williams, B. R. G., Dubensky, T. W., Han, Y., & Restifo, N. P. (2002) · Nature Medicine · doi:10.1038/nm813 · Cited by 269 · see citing works

Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Kerkar, S. P., Muranski, P. J., Kaiser, A., Boni, A., Sanchez-Perez, L. A., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254 · see citing works

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43490 · Cited by 253 · see citing works

Passive Immunotherapy of Cancer in Animals and Man

Rosenberg, S. A., & Terry, W. D. (1977) · Advances in cancer research · doi:10.1016/s0065-230x(08)60637-5 · Cited by 245 · see citing works

Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor

Varela‐Rohena, A., Molloy, P. E., Dunn, S. M., Li, Y., Suhoski, M. M., Carroll, R. G., Milicic, A., Mahon, T., Sutton, D. H., Laugel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1779 · Cited by 243 · see citing works

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases

Irvine, K. R., Rao, J. B., Rosenberg, S. A., & Restifo, N. P. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.238 · Cited by 233 · see citing works

Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

Wang, M., Bronte, V., Chen, P. W., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.9.4685 · Cited by 232 · see citing works

Type 17 CD8+ T cells display enhanced antitumor immunity

Hinrichs, C. S., Kaiser, A., Paulos, C. M., Cassard, L., Sanchez-Perez, L. A., Heemskerk, B., Wrzesinski, C., Borman, Z. A., Muranski, P. J., & Restifo, N. P. (2009) · Blood · doi:10.1182/blood-2009-02-203935 · Cited by 226 · see citing works

Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

Peng, W., Ye, Y., Rabinovich, B. A., Liu, C., Lou, Y., Zhang, M., Whittington, M., Yang, Y., Overwijk, W. W., Lizee, G. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0712 · Cited by 222 · see citing works

Adoptive immunotherapy of cancer using CD4+ T cells

Muranski, P. J., & Restifo, N. P. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.004 · Cited by 219 · see citing works

The critical role of Th1-dominant immunity in tumor immunology.

Nishimura, T., Nakui, M., Sato, M., Iwakabe, K., Kitamura, H., Sekimoto, M., Ohta, A., Koda, T., & Nishimura, S. (2000) · PubMed · doi:10.1007/pl00014051 · Cited by 211 · see citing works

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells

Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30414 · Cited by 202 · see citing works

Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells

Ji, Y., Pós, Z., Rao, M., Klebanoff, C. A., Yu, Z., Sukumar, M., Reger, R. N., Palmer, D. C., Borman, Z. A., Muranski, P. J., et al. (2011) · Nature Immunology · doi:10.1038/ni.2153 · Cited by 201 · see citing works

CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2

Antony, P. A., & Restifo, N. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000155049.26787.45 · Cited by 201 · see citing works

Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies

Singh, H., Figliola, M. J., Dawson, M. J., Huls, H. M., Olivares, S., Switzer, K. C., Mi, T., Maiti, S. N., Kebriaei, P., Lee, D. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3843 · Cited by 199 · see citing works

Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity

Yen, H., Harris, T. J., Wada, S., Grosso, J. F., Getnet, D., Goldberg, M. V., Liang, K., Bruno, T. C., Pyle, K. J., Chan, S.-L., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900368 · Cited by 195 · see citing works

Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy

Gattinoni, L., Ji, Y., & Restifo, N. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0356 · Cited by 175 · see citing works

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.

Seung, L. P., Rowley, D. A., Dubey, P., & Schreiber, H. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6254 · Cited by 170 · see citing works

Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy

Itzhaki, O., Hovav, E., Ziporen, Y., Levy, D., Kubi, A., Zikich, D., Hershkovitz, L., Treves, A. J., Shalmon, B., Zippel, D. B., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209c94c · Cited by 170 · see citing works

Analysis of the genome to personalize therapy for melanoma

Davies, M. A., & Samuels, Y. (2010) · Oncogene · doi:10.1038/onc.2010.323 · Cited by 167 · see citing works

Transferred melanoma-specific CD8 + T cells persist, mediate tumor regression, and acquire central memory phenotype

Chapuis, A. G., Thompson, J. A., Margolin, K. A., Rodmyre, R. M., Lai, I. P., Dowdy, K., Farrar, E. A., Bhatia, S., Sabath, D. E., Cao, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113748109 · Cited by 163 · see citing works

A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer

Chinnasamy, N., Wargo, J. A., Yu, Z., Rao, M., Frankel, T. L., Riley, J. P., Hong, J. J., Parkhurst, M. R., Feldman, S. A., Schrump, D. S., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001775 · Cited by 161 · see citing works

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice

Wang, X., Berger, C., Wong, C. W., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2010) · Blood · doi:10.1182/blood-2010-10-310599 · Cited by 160 · see citing works

Intravital Imaging Reveals Distinct Dynamics for Natural Killer and CD8+ T Cells during Tumor Regression

Deguine, J., Bréart, B., Lemaı̂tre, F., Santo, J. P. D., & Bousso, P. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.016 · Cited by 156 · see citing works

Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regimens That Use Two Different Vectors

Irvine, K. R., Chamberlain, R. S., Shulman, E., Surman, D. R., Rosenberg, S. A., & Restifo, N. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.21.1595 · Cited by 155 · see citing works

Bcl-2 overexpression enhances tumor-specific T-cell survival.

Charo, J., Finkelstein, S., Grewal, N. S., Restifo, N., Robbins, P., & Rosenberg, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2006 · Cited by 142 · see citing works

Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen

Chen, P. W., Wang, M., Bronte, V., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.224 · Cited by 138 · see citing works

De novoInduction of a Cancer/Testis Antigen by 5-Aza-2′-Deoxycytidine Augments Adoptive Immunotherapy in a Murine Tumor Model

Guo, Z. S., Hong, J. A., Irvine, K. R., Chen, G. A., Spiess, P. J., Liu, Y., Zeng, G., Wunderlich, J. R., Nguyen, D. M., Restifo, N. P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3020 · Cited by 137 · see citing works

Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.

Fefer, A. (1969) · PubMed · Cited by 131 · see citing works

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

Palmer, D. C., Chan, C., Gattinoni, L., Wrzesinski, C., Paulos, C. M., Hinrichs, C. S., Powell, D. J., Klebanoff, C. A., Finkelstein, S. E., Fariss, R. N., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710929105 · Cited by 130 · see citing works

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression

Rao, J. B., Chamberlain, R. S., Bronte, V., Carroll, M. W., Irvine, K. R., Moss, B., Rosenberg, S. A., & Restifo, N. P. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3357 · Cited by 125 · see citing works

Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.

Cheever, M. A., Greenberg, P. D., & Fefer, A. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.2.711 · Cited by 119 · see citing works

IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.

Bronte, V., Tsung, K., Rao, J. B., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.10.5282 · Cited by 117 · see citing works

Adoptive T cell therapy of cancer

Brenner, M. K., & Heslop, H. E. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.020 · Cited by 114 · see citing works

Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction

Palmer, D. C., Balasubramaniam, S., Hanada, K., Wrzesinski, C., Yu, Z., Farid, S. S., Theoret, M. R., Hwang, L. N., Klebanoff, C. A., Gattinoni, L., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7209 · Cited by 112 · see citing works

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells

Vatakis, D. N., Koya, R. C., Nixon, C. C., Liu, W., Kim, S. G., Avancena, P., Bristol, G. C., Baltimore, D., Kohn, D. B., Ribas, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115050108 · Cited by 106 · see citing works

Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma

Yeh, S., Karne, N. K., Kerkar, S. P., et al. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.12.004 · Cited by 105 · see citing works

Regulatory T Cells Selectively Control CD8+ T Cell Effector Pool Size via IL-2 Restriction

Kastenmüller, W., Gasteiger, G., Subramanian, N., Sparwasser, T. D., Busch, D. H., Belkaid, Y., Drexler, I., & Germain, R. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101649 · Cited by 102 · see citing works

Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies

Kerkar, S. P., Sanchez-Perez, L. A., Yang, S., Borman, Z. A., Muranski, P. J., Ji, Y., Chinnasamy, D., Kaiser, A., Hinrichs, C. S., Klebanoff, C. A., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182187600 · Cited by 99 · see citing works

Bispecific antibodies engage T cells for antitumor immunotherapy

Choi, B. D., Cai, M., Bigner, D. D., Mehta, A. I., Kuan, C.-T., & Sampson, J. H. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.572874 · Cited by 88 · see citing works

Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression

Wargo, J. A., Robbins, P. F., Li, Y., Zhao, Y., El‐Gamil, M., Caragacianu, D. L., Zheng, Z., Hong, J. A., Downey, S. G., Schrump, D. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0562-x · Cited by 87 · see citing works

Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase

Frankel, T. L., Burns, W. R., Peng, P. D., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000189 · Cited by 83 · see citing works

Targeting stroma to treat cancers

Engels, B., Rowley, D. A., & Schreiber, H. W. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.008 · Cited by 75 · see citing works

Autoimmunity and the Immunotherapy of Cancer: Targeting the "Self" to Destroy the "Other"

Overwijk, W. W., & Restifo, N. P. (2000) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v20.i6.10 · Cited by 74 · see citing works

T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model

Abad, J., Wrzensinski, C., Overwijk, W. W., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815c193f · Cited by 74 · see citing works

Of Mice, Not Men: No Evidence for Graft-versus-Host Disease in Humans Receiving T-Cell Receptor–Transduced Autologous T Cells

Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.195 · Cited by 67 · see citing works

Pharmacologic Induction of CD8 + T Cell Memory: Better Living Through Chemistry

Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000302 · Cited by 61 · see citing works

Prospects and Limitations of T Cell Receptor Gene Therapy

Jorritsma, A., Schotte, R., Coccoris, M., et al. (2011) · Current Gene Therapy · doi:10.2174/156652311796150390 · Cited by 61 · see citing works

Erratum: TH17 cells in tumour immunity and immunotherapy

Zou, W., & Restifo, N. P. (2011) · Nature reviews. Immunology · doi:10.1038/nri3029 · Cited by 60 · see citing works

Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell–Mediated Targeting of Carcinoembryonic Antigen

Bos, R., van Duikeren, S., Morreau, H. M., Franken, K. L. M. C., Schumacher, T. N., Haanen, J. B. A. G., van der Burg, S. H., Melief, C. J. M., & Offringa, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1864 · Cited by 60 · see citing works

Construction and Characterization of a Triple-Recombinant Vaccinia Virus Encoding B7-1, Interleukin 12, and a Model Tumor Antigen

Carroll, M. W., Moss, B., Overwijk, W. W., Surman, D. R., Restifo, N. P., & Tsung, K. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.24.1881 · Cited by 47 · see citing works

The Yin and Yang of Interleukin-2–Mediated Immunotherapy

Bluestone, J. A. (2011) · New England Journal of Medicine · doi:10.1056/nejme1110900 · Cited by 44 · see citing works

Oncogene-Targeting T Cells Reject Large Tumors while Oncogene Inactivation Selects Escape Variants in Mouse Models of Cancer

Anders, K., Buschow, C., Herrmann, A., Milojkovic, A., Loddenkemper, C., Kammertoens, T., Daniel, P. T., Yu, H., Charo, J., & Blankenstein, T. J. F. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.019 · Cited by 43 · see citing works

Antigen choice in adoptive T-cell therapy of cancer

Offringa, R. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.006 · Cited by 42 · see citing works

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

Boni, A., Muranski, P., Cassard, L., Wrzesinski, C., Paulos, C., Palmer, D., Gattinoni, L., Hinrichs, C., Chan, C.-C., Rosenberg, S., et al. (2008) · Blood · doi:10.1182/blood-2008-07-169797 · Cited by 42 · see citing works

Genetically modulating T-cell function to target cancer.

Merhavi-Shoham, E., Haga-Friedman, A., & Cohen, C. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.006 · Cited by 42 · see citing works

Delving into somatic variation in sporadic melanoma

Walia, V., Mu, E. W., Lin, J., & Samuels, Y. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00976.x · Cited by 41 · see citing works

Combination of targeted therapy and immunotherapy in melanoma

Blank, C. U., Hooijkaas, A. I., Haanen, J. B. A. G., & Schumacher, T. N. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1079-2 · Cited by 41 · see citing works

Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.

Irvine, K. R., Parkhurst, M. R., Shulman, E., et al. (1999) · PubMed · Cited by 39 · see citing works

Does IL-17 promote tumor growth?

Muranski, P. J., & Restifo, N. P. (2009) · Blood · doi:10.1182/blood-2009-04-215541 · Cited by 31 · see citing works

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination

Klebanoff, C. A., Yu, Z., Hwang, L. N., Palmer, D. C., Gattinoni, L., & Restifo, N. P. (2009) · Blood · doi:10.1182/blood-2008-12-192419 · Cited by 30 · see citing works

Molecular Aspects of Tanning

Gilchrest, B. A. (2011) · Journal of Investigative Dermatology · doi:10.1038/skinbio.2011.6 · Cited by 30 · see citing works

Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity

Ha, S. P., Klemen, N. D., Kinnebrew, G. H., Brandmaier, A., Marsh, J. W., Hangoc, G., Palmer, D. C., Restifo, N. P., Cornetta, K. G., Broxmeyer, H. E., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43274 · Cited by 22 · see citing works

Adoptive Therapy Using Antigen-Specific T-Cell Clones

Yee, C. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacba8 · Cited by 20 · see citing works

Memory in disguise

Sallusto, F., & Lanzavecchia, A. (2011) · Nature Medicine · doi:10.1038/nm.2502 · Cited by 19 · see citing works

Can Antitumor Immunity Help to Explain “Oncogene Addiction”?

Restifo, N. P. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.002 · Cited by 19 · see citing works

Recombinant DNA Advisory Committee.

(1983) · PubMed · Cited by 19 · see citing works

Recent Advances in Therapeutic Cancer Vaccines

Schlom, J. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1200 · Cited by 11 · see citing works

Clinical Experience with Gene Therapy and Bispecific Antibodies for T Cell-based Therapy of Cancer

Baeuerle, P. A., & Itin, C. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800785005 · Cited by 9 · see citing works

Microenvironmental regulation of tumor progression and metastasis

Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · see citing works

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works

Targeting Tumor Microenvironment for Cancer Therapy

Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187 · see citing works

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034 · see citing works

Systemic Immunity Is Required for Effective Cancer Immunotherapy

Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · see citing works

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · see citing works

CAR T Cell Therapy for Solid Tumors

Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909 · see citing works

The who's who of <scp>T</scp> ‐cell differentiation: Human memory <scp>T</scp> ‐cell subsets

Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M., & Lugli, E. (2013) · European Journal of Immunology · doi:10.1002/eji.201343751 · Cited by 817 · see citing works

CAR-NK cells: A promising cellular immunotherapy for cancer

Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800 · see citing works

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins

Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702 · see citing works

The two faces of IL-6 in the tumor microenvironment

Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.008 · Cited by 693 · see citing works

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints

Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512 · see citing works

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells

Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501 · see citing works

Interleukin 12: still a promising candidate for tumor immunotherapy?

Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495 · see citing works

Exploiting the curative potential of adoptive T‐cell therapy for cancer

Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466 · see citing works

Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells

Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442 · see citing works

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Valero, C., Lee, M., Hoen, D., Weiss, K., Kelly, D. W., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20935-9 · Cited by 441 · see citing works

Biomaterials and emerging anticancer therapeutics: engineering the microenvironment

Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407 · see citing works

Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy

Mai, Z., Lin, Y., Lin, P., Zhao, X., & Cui, L. (2024) · Cell Death &amp; Disease · doi:10.1038/s41419-024-06697-4 · Cited by 398 · see citing works

Mechanisms regulating T-cell infiltration and activity in solid tumors

Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369 · see citing works

The immune system and cancer evasion strategies: therapeutic concepts

Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304 · see citing works

Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells

Miao, Y., Yang, H., Levorse, J., Yuan, S., Polak, L., Sribour, M., Singh, B., Rosenblum, M. D., & Fuchs, E. (2019) · Cell · doi:10.1016/j.cell.2019.03.025 · Cited by 299 · see citing works

Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion

Frangieh, C. J., Melms, J. C., Thakore, P. I., Geiger-Schuller, K. R., Ho, P., Luoma, A. M., Cleary, B., Jerby-Arnon, L., Malu, S., Cuoco, M. S., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00779-1 · Cited by 276 · see citing works

Engineering and physical sciences in oncology: challenges and opportunities

Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273 · see citing works

Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy

Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250 · see citing works

In vivo discovery of immunotherapy targets in the tumour microenvironment

Zhou, P., Shaffer, D. R., Alvarez Arias, D. A., Nakazaki, Y., Pos, W., Torres, A. J., Cremasco, V., Dougan, S. K., Cowley, G. S., Elpek, K., et al. (2014) · Nature · doi:10.1038/nature12988 · Cited by 237 · see citing works

Long-lasting stem cell–like memory CD8 ⁺ T cells with a naïve-like profile upon yellow fever vaccination

Fuertes Marraco, S. A., Soneson, C., Cagnon, L., Gannon, P. O., Allard, M., Maillard, S. A., Montandon, N., Rufer, N., Waldvogel, S., Delorenzi, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3700 · Cited by 206 · see citing works

Hostile, Hypoxia–A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists

Sitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215 · see citing works

Genetic determinants of co-accessible chromatin regions in activated T cells across humans

Gate, R. E., Cheng, C. S., Aiden, A. P., Siba, A., Tabaka, M., Lituiev, D., Machol, I., Gordon, M. G., Subramaniam, M., Shamim, M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0156-2 · Cited by 181 · see citing works

Engineering patient-specific cancer immunotherapies

Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208 · see citing works

Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells.

Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205 · see citing works

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0400-z · Cited by 203 · see citing works

Involvement of a Non-Human Sialic Acid in Human Cancer

Samraj, A. N., Läubli, H., Varki, N., & Varki, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00033 · Cited by 196 · see citing works

Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12

Uribe-Herranz, M., Bittinger, K., Rafail, S., Guedan, S., Pierini, S., Tanes, C., Ganetsky, A., Morgan, M. A., Gill, S., Tanyi, J. L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.94952 · Cited by 175 · see citing works

Tumor-specific IL-9–producing CD8 ⁺ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers

Lu, Y., Hong, B., Li, H., Zheng, Y., Zhang, M., Wang, S., Qian, J., & Yi, Q. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317431111 · Cited by 146 · see citing works

Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA

Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.041 · Cited by 132 · see citing works

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy

Liu, Z., Ravindranathan, R., Li, J., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1091554 · Cited by 113 · see citing works

IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age

Tsukamoto, H., Senju, S., Matsumura, K., Swain, S. L., & Nishimura, Y. (2015) · Nature Communications · doi:10.1038/ncomms7702 · Cited by 104 · see citing works

Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma

Arakawa, A., Vollmer, S., Tietze, J., Galinski, A., Heppt, M. V., Bürdek, M., Berking, C., & Prinz, J. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01336 · Cited by 74 · see citing works

Pegylated <scp>IL</scp>‐10 induces cancer immunity: The surprising role of IL‐10 as a potent inducer of IFN‐γ‐mediated CD8⁺ T cell cytotoxicity

Mumm, J. B., & Oft, M. (2013) · BioEssays · doi:10.1002/bies.201300004 · Cited by 53 · see citing works

Nuclear Phosphoproteomic Screen Uncovers ACLY as Mediator of IL-2-induced Proliferation of CD4+ T lymphocytes

Osinalde, N., Mitxelena, J., Sánchez-Quiles, V., Akimov, V., Aloria, K., Arizmendi, J. M., Zubiaga, A. M., Blagoev, B., & Kratchmarova, I. (2016) · Molecular &amp; Cellular Proteomics · doi:10.1074/mcp.m115.057158 · Cited by 48 · see citing works

Microbiota Modulation of Myeloid Cells in Cancer Therapy

Goldszmid, R. S., Dzutsev, A., Viaud, S., Zitvogel, L., Restifo, N. P., & Trinchieri, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0225 · Cited by 46 · see citing works

Engineering of synthetic cellular microenvironments: Implications for immunity

Adutler-Lieber, S., Zaretsky, I., Platzman, I., Deeg, J., Friedman, N., Spatz, J. P., & Geiger, B. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.05.003 · Cited by 39 · see citing works

New chimeric antigen receptor design for solid tumors

Wang, Y., Luo, F., Yang, J., Zhao, C., & Chu, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01934 · Cited by 32 · see citing works

Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s

DeRenzo, C., & Gottschalk, S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_10 · Cited by 12 · see citing works

PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction

Li, X., He, Y., Wu, J., Wang, Z., Zhao, X., Zhang, Y., Pan, B., Tang, Y., & Han, J. (2026) · PubMed · doi:10.1126/sciadv.aed6373 · Cited by 1 · see citing works

Adoptive Immunotherapy

Bollard, C. M., & Heslop, H. E. (2009) · doi:10.1002/9781444303513.ch59

[Immunoprophylactic and immunotherapeutic effects of adoptively transferred LAK cells on L615 leukemia suffering mice].

Zhao, T. H. (1993) · PubMed

Adoptive cellular immunotherapy for cancer

Shang, Y., Wang, Z.-B., Ma, Y., et al. (2013) · Guoji zhongliuxue zazhi · doi:10.3760/cma.j.issn.1673-422x.2013.02.007

Cellular Adoptive Immunotherapy after Bone Marrow Transplantation

Riddell, S. R., & Greenberg, P. D. (1995) · Cancer treatment and research · doi:10.1007/978-1-4615-2013-9_16 · Cited by 23 · see citing works

Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators

Debele, T. A., Yeh, C.-F., & Su, W. (2020) · Cancers · doi:10.3390/cancers12123773 · Cited by 85 · see citing works